Skip Navigation
 

Translational Research Unit (TRU)

Clinical Trials

Clinical trials, also called research studies, are managed by government agencies, educational institutions, private not-for-profit organizations, or commercial businesses, to develop, produce, and evaluate the effectiveness of new treatments and therapies for diseases. New trials are added on a routine basis, and many clinical trials accept only a limited number of participants. MUSC participates in a large number of clinical trials. If you are interested in treatment for a specific condition, search our neurosciences clinical trial list below, or visit the other clinical trials databases to review your options.


Clinical Trials Databases


MUSC Neurosciences Clinical Trials

Neuro-Oncology

A Phase II Clinical Trial Evaluating DCVax-Brain, Autologous Dendritic Cells (DC) Pulsed with Tumor Lysate Antigen for the Treatment for Glioblastoma
Investigator: Scott Lindhorst, M.D.
Coordinator: Michele DeCandio, RN, OCN, CCRP (843-792-9016, decandio@musc.edu)

A Phase I-II Trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas
Investigator: Scott Lindhorst, M.D.
Coordinator: Michele DeCandio, RN, OCN, CCRP (843-792-9016, decandio@musc.edu)

Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients with High-Grade Gliomas
Investigator: Scott Lindhorst, M.D.
Coordinator: Michele DeCandio, RN, OCN, CCRP (843-792-9016, decandio@musc.edu)

Phase III Intergroup Study of Temozolomide Alone Versus Radiotherapy with Concomitant and Adjuvant Temozolomide Versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients 1p/19q Co-Deleted Anaplastic Glioma
Investigator: Scott Lindhorst, M.D.
Coordinator: Susan Shannon (843-792-9251, shannsu@musc.edu)

Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial
Investigator: Scott Lindhorst, M.D.
Coordinator: Susan Shannon (843-792-9251, shannsu@musc.edu)

Imaging Biomarkers of Tissue Miscrostructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment with Bevacizumab for Progressive Disease
Investigator: Scott Lindhorst, M.D.
Coordinator: Susan Shannon (843-792-9251, shannsu@musc.edu)

Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab plus Vorinostat in Adults with Recurrent Glioblastoma
Investigator: Scott Lindhorst, M.D.
Coordinator: Susan Shannon (843-792-9251, shannsu@musc.edu)

Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Investigator: Scott Lindhorst, M.D.
Coordinator: Susan Shannon (843-792-9251, shannsu@musc.edu)

A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (GBM)
Investigator: Scott Lindhorst, M.D.
Coordinator: Michele DeCandio, RN, OCN, CCRP (843-792-9016, decandio@musc.edu)

A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adults with Recurrent Glioblastoma Multiforme
Investigator: Scott Lindhorst, M.D.
Coordinator: Michele DeCandio, RN, OCN, CCRP (843-792-9016, decandio@musc.edu)


Movement Disorders

Parkinson's Disease (PD)

Istradefylline study for people with dyskinesias and off time from Parkinson’s Disease: Evaluates the safety and efficacy of istradefylline, a new medication aimed at treating symptom Fluctuations in moderate to advanced PD.
Coordinator: Shonna Jenkins (843-792-9115, jenkisho@musc.edu)

Tele-Neurology: Remote assessments of patients with PD in South Carolina via tele-neurology: Validation of the new Movement Disorder Society (MDS)-Unified Parkinson’s Disease Rating Scale.
Coordinator: Shonna Jenkins (843-792-9115, jenkisho@musc.edu)

Steady PD: This study will start enrollment in a medication called isradipine can slow down the progression of PD in people with early, untreated disease.
Coordinator: Shonna Jenkins (843-792-9115, jenkisho@musc.edu)

Eagle Eye: Evaluates whether computer analysis of eye movements can help us in the understanding and measurement of cognitive thinking problems in PD.
Coordinator: Dr. Jenna Renfroe (843-792-6096, renfroe@musc.edu)

Tardive Dyskinesia

Dutetrabenazine: A study of SD-809 (Dutetrabenazine) for the treatment of moderate to severe tardive dyskinesia (drug-induced movement disorder).
Coordinator: Nancy Feracco (843-792-7859, feracco@musc.edu)

Essential Tremor

A Pilot Study to Assess the Effects of pre-SMA LF-TMS for the Treatment of Essential Tremor
Coordinator: Shonna Jenkins (843-792-9115, jenkisho@musc.edu)
 


Epilepsy

The Human Epilepsy Project
Investigator: Jonathan Halford, M.D.                               
Coordinator: Becky Hamrick (843-792-3855, hamrickr@musc.edu)

fMRI in Anterior Temporal Epilepsy Surgery
Investigator: Leo Bonhila, M.D.                                  
Coordinator: Sheri Davis (843-792-2845, davshe@musc.edu)

Location of Seizures with Post Ictal MRI
Investigator: Leo Bonhila, M.D.                                  
Coordinator: Sheri Davis (843-792-2845, davshe@musc.edu)

Histological Analysis Epilepsy Surgery Tissue
Investigator: Leo Bonhila, M.D.                                  
Coordinator: Sheri Davis (843-792-2845, davshe@musc.edu)

Advance Brain Imaging
Investigator: Leo Bonhila, M.D.                                  
Coordinator: Sheri Davis (843-792-2845, davshe@musc.edu)

Neuropsychological Evaluation During Routine Intracranial Recording
Investigator: Leo Bonhila, M.D.                                  
Coordinator: Sheri Davis (843-792-2845, davshe@musc.edu)

A Pivotal, Phase III Trial of Detecting Generalized Tonic-Clonic Seizures with a Seizure Detection and Warning System in Epilepsy Patients
Investigator:  Jonathan Halford, M.D.
Coordinator:  Becky Hamrick (843-792-3855, hamrickr@musc.edu)

An Open-Label, Single Dose, Randomized, Crossover Pharmacokinetic Study to Determine Bioequivalence and Assess Dose Proportionality, Stafety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat) in Patients with Epilepsy.
Investigator:  Jonathan Halford, M.D.
Coordinator:  Becky Hamrick (843-792-3855, hamrickr@musc.edu)

 

Aphasia

Transcranial Direct Current Stimulation and Aphasia Treatment Outcomes
Investigator: Leo Bonhila, M.D., David Bachman, M.D.                           
Coordinator: Sheri Davis (843-792-2845, davshe@musc.edu)

 

Institute for Applied Neurosciences

Blink Reflex Characteristics
Investigator: Leonardo Bonilha, M.D., Ph.D.
Coordinator: Megan Hicks (843-792-3294, hicksmp@musc.edu)
 

 

Useful links:

 
 
 

© 2012  Medical University of South Carolina | Disclaimer | Contact the Webmaster